Install
Master the Science of Success through aspirational coverage for executive-level decisions, leadership, management, strategy and commercialization professionals.
- 88articles · 30d
- 2+ hour agolatest article
- Aug 14, 2026earliest in window
- 93%with images
- 232avg words
- Business & Industrial 61
- Medical 48
- Economy, Business & Finance 44
- Finance & Business 28
- Health 24
- Health & Wellness 24
- Science & Technology 18
- Science & Nature 6
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Boards, AI, and 500 Years of Experience in Life Sciences: Takeaways from the 2026 Life Sciences Board Forum
2+ hour, 29+ min ago (92+ words) This June, ten of the life sciences industry’s most respected board members came to New York for Accenture’s second annual Life Sciences Board Forum for something this industr... Ten life sciences board directors on AI's three hardest questions: developing the…...
The Agentic AI Revolution in Biopharma
2+ day, 3+ hour ago (1556+ words) How agentic artificial intelligence is transforming the value chain from discovery to commercialization. The biopharmaceutical industry is undergoing a profound transformation, driven by the emergence of agentic artificial intelligence (AI). Unlike traditional AI models that require continuous human guidance, agentic…...
Unlocking the Future of Real-World Data & Research | PharmExec
3+ day, 14+ hour ago (40+ words) Unlocking the Future of Real-World Data & Research Pharmaceutical Executive Pharmaceutical Executive Daily: Moonwalk Biosciences' $70 Million Series B Trusted Research Environments Are Reshaping Real-World Data Access: Q&A with Mark Cziraky FDA Approves Zanvastro for Alexander Disease in Pediatrics & Adults...
Pharmaceutical Executive Daily: Novartis and BMS Halt CAR-T Trials
1+ week, 3+ day ago (566+ words) Novartis and Bristol Myers Squibb pause autoimmune CAR-T trials over safety concerns, a dealmaking roundup covers Alteogen's licensing deal with Novartis, NewBiologix's gene therapy partnership with Synastra, and RedHill's acquisition of Rebyota and Clenpiq from Ferring, and Lexi Cogswell and…...
Moving Beyond the Sample Size Guess: Lessons from 60 Million Clinical Trial Simulations
2+ week, 3+ day ago (118+ words) Pharmaceutical Executive Why traditional power calculations leave asset value on the table, and how adaptive frameworks change the math on risk. Most Phase 2 trials are sized on a guess seen as mathematics. You are in the trial design meeting, your…...
Infrastructure First: A Framework for Scaling AI in Life Sciences
2+ week, 5+ day ago (219+ words) You've seen it before: an AI pilot that works in testing, then stalls the moment someone asks you to reproduce the result. The cause usually isn't the model—it's what wasn't built around it. Komodo Health built this framework from…...
Exec on Execs: Identifying the Gaps | PharmExec
2+ week, 5+ day ago (58+ words) Exec on Execs: Identifying the Gaps Pharmaceutical Executive The Operational Reality of Reshoring Pharma Manufacturing: Q&A with Rohit Tripathi Your Questions Answered: What This Week's Rare Disease and Specialty Drug News Tells Us About Where the Industry Is Heading…...
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
3+ week, 1+ day ago (340+ words) Amplitude Therapeutics enters a collaboration with Eli Lilly to develop trans-amplifying RNA vaccines, while Chai Discovery partners with Bristol Myers Squibb to deploy its AI molecular folding and design models across BMS's antibody discovery portfolio. As of August 21, financial terms…...